Role of ribavirin in interferon-free therapy for the treatment of hepatitis C virus

Van der Meer, 2012, Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis, JAMA, 308, 93, 10.1001/jama.2012.144878 Bruno, 2007, Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study, Hepatology, 45, 579, 10.1002/hep.21492 Bruno, 2010, Sustained virologic response prevents the development of esophageal varices in compensated Child–Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study, Hepatology, 51, 2069, 10.1002/hep.23528 Guías AEEH-SEIMC de manejo de la hepatitis C. Available in: www.aeeh.es/.www.seimc.org 2017, EASL recommendations on treatment of hepatitis C 2016, J Hepatol, 66, 153, 10.1016/j.jhep.2016.09.001 American Association for the Study of Liver Diseases, Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. Available in: http://www.hcvguidelines.org/ Bronowicki, 2006, Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin, Gastroenterology, 131, 1040, 10.1053/j.gastro.2006.07.022 Hézode, 2009, Telaprevir and peginterferon with or without ribavirin for chronic HCV infection, N Engl J Med, 360, 1839, 10.1056/NEJMoa0807650 Kowdley, 2014, Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1, N Engl J Med, 370, 222, 10.1056/NEJMoa1306227 Lawitz, 2014, Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment- naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial, Lancet, 383, 870, 10.1016/S0140-6736(13)62121-2 Ferenci, 2014, ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV, N Engl J Med, 370, 1983, 10.1056/NEJMoa1402338 Poordad, 2014, ABT-450/r-ombitasvir and dasabuvir with ribavirin for Hepatitis C with cirrhosis, N Engl J Med, 370, 1973, 10.1056/NEJMoa1402869 Zeuzem, 2015, Grazoprevir–elbasvir combination therapy for treatment-naïve cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4 or 6 infection, Ann Intern Med, 63, 1, 10.7326/M15-0785 Rockstroh, 2015, Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial, Lancet HIV, 2, e319, 10.1016/S2352-3018(15)00114-9 Zeuzem, 2015, Predictors of response to grazoprevir/elbasvir among HCV genotype 1 (GT1)-infected patients: integrated analysis of Phase 2–3 trials, Hepatology, 62, 554A Kwo, 2015, Efficacy and safety of grazoprevir/elbasvir plus or minus RBV for 12 weeks in patients with HCV G1 or G4 infection who previously failed peginterferon/RBV: C-EDGE treatment-experienced trial, J Hepatol, 62, S674, 10.1016/S0168-8278(15)31088-6 Zeuzem, 2015, Prevalence of pretreatment NS5A resistance associated variants in genotype 1 patients across different regions using deep sequencing and effect on treatment outcome with LDV/SOF, Hepatology, 62, 254A Sarrazin, 2016, The importance of resistance to direct antiviral drugs in HCV infection in clinical practice, J Hepatol, 64, 486, 10.1016/j.jhep.2015.09.011 Reddy, 2015, Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis, Hepatology, 62, 79, 10.1002/hep.27826 Bourlière, 2015, Ledipasvir and sofosbuvir for 12 weeks with ribavirin or for 24 weeks alone in patients with genotype 1 HCV infection and cirrhosis in whom prior protease inhibitor therapy failed (SIRIUS): a randomized, double-blind, phase 2 trial, Lancet Infect Dis, 15, 397, 10.1016/S1473-3099(15)70050-2 Pol, 2015, Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the French observational cohort ANRS C022 HEPATHER, J Hepatol, 62, S258, 10.1016/S0168-8278(15)30149-5 Hézode, 2015, Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naïve and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomized, open-label trial, Lancet, 385, 2502, 10.1016/S0140-6736(15)60159-3 Asselah, 2015, High efficacy of elbasvir and grazoprevir with or without ribavirin in 103 treatment-naive and experienced patients with HCV genotype 4 infection: a pooled analysis, Hepatology, 62, 208A Nelson, 2015, All-oral 12-week combination treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 Phase III Study, Hepatology, 61, 1127, 10.1002/hep.27726 Leroy, 2016, Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+), Hepatology, 63, 1430, 10.1002/hep.28473 Foster, 2015, Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection, N Engl J Med, 373, 2608, 10.1056/NEJMoa1512612 Gane, 2014, Sofosbuvir/ledispasvir fixed dose combination is safe and effective in difficult-to-treat populations including genotype-3 patients, decompensated genotype-1 patients, and genotype-1 patients with prior sofosbuvir treatment experience, J Hepatol, 60, S3, 10.1016/S0168-8278(14)60008-8 Charlton, 2015, Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease, Gastroenterology, 149, 649, 10.1053/j.gastro.2015.05.010 Foster, 2016, Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis, J Hepatol, 64, 1224, 10.1016/j.jhep.2016.01.029 Poordad, 2015, Daclatasvir, sofosbuvir and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: phase 3 ALLY-1 study, J Hepatol, 62, S261, 10.1016/S0168-8278(15)30154-9 Foster, 2015, Treatment of decompensated HCV cirrhosis in patients with diverse genotypes: 12 weeks sofosbuvir and NS5A inhibitors with/without ribavirin is effective in HCV genotypes 1 and 3, J Hepatol, 62, S190, 10.1016/S0168-8278(15)30009-X Curry, 2015, Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis, N Engl J Med, 373, 2618, 10.1056/NEJMoa1512614 Pawlotsky, 2016, Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens, Gastroenterology, 151, 70, 10.1053/j.gastro.2016.04.003 Sarrazin, 2016, The importance of resistance to direct antiviral drugs in HCV infections in clinical practice, J Hepatol, 64, 486, 10.1016/j.jhep.2015.09.011 Pawlotsky, 2004, Antiviral action of ribavirin in chronic hepatitis C, Gastroenterology, 126, 703, 10.1053/j.gastro.2003.12.002 Thomas, 2012, The application and mechanism of action of ribavirin in therapy of hepatitis C, Antivir Chem Chemother, 23, 1, 10.3851/IMP2125 Dietz, 2013, Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients, J Virol, 87, 6172, 10.1128/JVI.02778-12 Mihm, 2014, Impact of ribavirin priming on viral kinetics and treatment response in chronic hepatitis C genotype 1 infection, J Viral Hepat, 21, 42, 10.1111/jvh.12124 Rotman, 2014, Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C, Gut, 63, 161, 10.1136/gutjnl-2012-303852 Hézode, 2006, Effect of an IMPDH inhibitor, merimepodib (MMPD), assessed alone or in combination with ribavirin, on HCV replication: implications regarding ribavirin's mechanisms of action, Hepatology, 44, 615A Lawitz, 2015, A phase 3, open-label, single arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naive or – experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST-2, J Hepatol, 62, S264, 10.1016/S0168-8278(15)30158-6 Sarrazin, 2015, The prevalence and the effect of HCV NS5a resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir/sofosbuvir +/– RBV, J Hepatol, 62, S620, 10.1016/S0168-8278(15)30976-4